Hyperkalemia Quality Improvement Program (HK-QIP) Study

Other illness

• Pseudohyperkalemia signs and symptoms, such as hemolyzed blood specimen due to excessive fist clenching to make veins prominent, difficult or traumatic venipuncture, or history of severe leukocytosis or thrombocytosis.
• Patients with cardiac arrhythmias that require immediate treatment
• Patients scheduled for renal transplant or with a history of renal transplant.
• History of malignancy except for:
  • 7.1 Malignancy treated with curative intent and with no known active disease within 3 years before the enrolment and of low potential risk for recurrence.
  • 7.2 Adequately treated non-melanoma skin cancer or lentigo malignancy without evidence of disease.
  • 7.3 Adequately treated carcinoma in situ without evidence of disease.

Other

• Patients on dialysis.
• Patients with acute kidney injury (AKI) or diabetic ketoacidosis (DKA).
• Life expectancy \< 48 weeks.
• Be participating in other intervention clinical trials.
• Judgment by the HCP that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.

• Age ≥18 years, at the time of signing the informed consent.
• HK (sK+ \> 5.0 mmol/L) within 48 hours before enrolment.
• Patients diagnosed as chronic kidney disease with eGFR\>10 ml/min/1.73m2 based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine Equation (2021). See 8.3.4 for detailed equation.
• Capable of giving signed informed consent as described in Appendix A which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.